Additionally, anti-PD-L1 plus anti-TGF-β combination treatment led to upregulation of additional chemokines such as Cxcl1 and Cxcl2 in tumor cells above and beyond those induced by either single treatment alone (Additional file 2, Table S1). The gene discussed is CXCL1; the disease is neoplasm.